Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy

Chemotherapy-induced neuropathy: A comprehensive survey

(2014) N.C. Miltenburg et al.   CANCER TREATMENT REVIEWS

The Development and Maintenance of Paclitaxel-induced Neuropathic Pain Require Activation of the Sphingosine 1-Phosphate Receptor Subtype 1

(2014) Kali Janes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

(2014) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

Thematic review series: Recent advances in the treatment of lysosomal storage diseases

(2014) James A. Shayman   JOURNAL OF LIPID RESEARCH

Impact of Chemotherapy-Induced Peripheral Neuropathy on Treatment Delivery in Nonmetastatic Breast Cancer

(2013) Rebecca M. Speck et al.   Journal of Oncology Practice

Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy

(2012) Brandi N. Reeves et al.   CANCER

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

(2012) C. Massard et al.   INVESTIGATIONAL NEW DRUGS

Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer

(2012) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies

(2011) P. Schöffski et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sphingolipid and Glycosphingolipid Metabolic Pathways in the Era of Sphingolipidomics

(2011) Alfred H. Merrill   CHEMICAL REVIEWS

Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome?

(2011) A. Othman et al.   DIABETOLOGIA

Characterization of two mutations in the SPTLC1 subunit of serine palmitoyltransferase associated with hereditary sensory and autonomic neuropathy type I

(2011) Annelies Rotthier et al.   HUMAN MUTATION

Oral l-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1

(2011) Kevin Garofalo et al.   JOURNAL OF CLINICAL INVESTIGATION

Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1

(2011) Charles L. Loprinzi et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations in the SPTLC2 Subunit of Serine Palmitoyltransferase Cause Hereditary Sensory and Autonomic Neuropathy Type I

(2010) Annelies Rotthier et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Hereditary Sensory Neuropathy Type 1 Is Caused by the Accumulation of Two Neurotoxic Sphingolipids

(2010) Anke Penno et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Deoxysphingoid bases as plasma markers in Diabetes mellitus

(2010) Mariana Bertea et al.   Lipids in Health and Disease

Role of satellite cell-derived l-serine in the dorsal root ganglion in paclitaxel-induced painful peripheral neuropathy

(2010) T. Kiya et al.   NEUROSCIENCE

Therapy of chemotherapy-induced peripheral neuropathy

(2009) Thomas J. Kaley et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

(2009) R. D. Baird et al.   MOLECULAR CANCER THERAPEUTICS

Hereditary sensory neuropathy type I

(2008) Michaela Auer-Grumbach   Orphanet Journal of Rare Diseases

The evolution of plasma cholesterol: Direct utility or a “spandrel” of hepatic lipid metabolism?

(2008) Patrick J. Babin et al.   PROGRESS IN LIPID RESEARCH